Drug Trial Radar · NCT00228982
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
Last checked: Nov 20, 2026Latest source record: Jul 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
784
Actual
Start
Oct 2004
Primary completion
Dec 2005
Study completion Dec 2005
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- First posted
- Sep 29, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.
Conditions
- Skin Diseases, Infectious
- Skin Diseases, Bacterial
- Staphylococcal Skin Infections
Interventions
Ceftobiprole medocarilDrug
VancomycinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical outcome (cure, failure, not evaluable) at 7-14 days after the end of therapy.Time frame: 7 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.